Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sinan Dheyauldeen"'
Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
Autor:
Ole Jakob Jørgensen, Johan Edvard Steineger, Andreas Hillarp, Erik Pareli Wåland, Pål André Holme, Ketil Heimdal, Sinan Dheyauldeen
Publikováno v:
Laryngoscope Investigative Otolaryngology, Vol 9, Iss 1, Pp n/a-n/a (2024)
Abstract Objectives The objective of this study was twofold: to determine the prevalence of arterial and venous thromboembolic events in the Norwegian Hereditary Hemorrhagic Telangiectasia (HHT) population, and to explore potential factors linked to
Externí odkaz:
https://doaj.org/article/008d2fa34dbe4fb092a7d2b9f4b29544
Autor:
Ralph Dollner Ph.D., Petter Lorentz Larsen M.D., Sinan Dheyauldeen M.D., Sverre Steinsvåg M.D.
Publikováno v:
Allergy & Rhinology, Vol 8 (2017)
Background Allergic Rhinitis and its Impact on Asthma guidelines recently recommended a treatment strategy for allergic rhinitis (AR) based on disease control rather than symptom severity by using a visual analog scale (VAS) to categorize control Obj
Externí odkaz:
https://doaj.org/article/2a7e340c6ecc4538b72bed5d73ac9e31
Publikováno v:
Rhinology. 59(2)
BACKGROUND: Different institutions use different grading systems for hereditary haemorrhagic telangiectasia (HHT)-associated epistaxis. It is important to have a universal, standardized grading system to compare and evaluate the effectiveness of diff
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 140(10)
Publikováno v:
Tidsskrift for Den norske legeforening.
Autor:
Anikka Michelsen, Thor Ueland, Sinan Dheyauldeen, Terje Osnes, Pål Aukrust, Ketil Heimdal, Johan Steineger
Publikováno v:
The Laryngoscope. 129:E44-E49
Objectives/hypothesis We aimed to investigate if vascular endothelial growth factor (VEGF) and other angiogenic and inflammatory factors correlated with the clinical presentation in hereditary hemorrhagic telangiectasia (HHT) patients, particularly i
Publikováno v:
The Laryngoscope. 128:2237-2244
Objectives/hypothesis Long-term follow-up of intranasal bevacizumab therapy in hereditary hemorrhagic telangiectasia (HHT). Study design Prospective, noncomparative study. Methods Patients treated for HHT-associated epistaxis by intranasal submucosal
Autor:
Else Merckoll, Sinan Dheyauldeen, Ketil Heimdal, John Magnar Slåstad, Johan Steineger, Erik Fink Eriksen
Publikováno v:
The Laryngoscope. 128:593-596
Intranasal bevacizumab injections have been used in treating hereditary hemorrhagic telangiectasia (HHT)-related epistaxis since 2009. It is believed to be a safe and effective treatment for a selected group of HHT patients in reducing frequency and
Publikováno v:
The Laryngoscope. 130
BACKGROUND Epistaxis is the most common symptom in patients with hereditary hemorrhagic telangiectasia (HHT), with the greatest negative impact on quality of life (QoL). Repeated intranasal submucosal bevacizumab injections (RISBI) is a relatively ne
Autor:
Johan, Steineger, Thor, Ueland, Pål, Aukrust, Anikka, Michelsen, Terje, Osnes, Ketil, Heimdal, Sinan, Dheyauldeen
Publikováno v:
The Laryngoscope. 129(1)
We aimed to investigate if vascular endothelial growth factor (VEGF) and other angiogenic and inflammatory factors correlated with the clinical presentation in hereditary hemorrhagic telangiectasia (HHT) patients, particularly in regard to the severi